Navigation Links
Enzyme shown to help protect genomic stability

Genomes throughout the animal kingdom and beyond are characterized by extensive segments that are inactive, lengthy stretches of DNA containing multiple genes that are closed to gene transcription. Scientists believe one reason for this broad gene silencing is the vital need for genomic stability, for protection against unwanted recombinations of genetic material or other disruptions of the genome's integrity.

Genomic instability, particularly in the regions at the ends of the chromosomes known as telomeres, has been linked to aging in humans and an elevated risk for aging-related diseases, the most prominent of which is cancer. For this reason, insights into the mechanisms of gene silencing could provide important guideposts for new approaches to retarding aging or treating cancer.

Now, an investigation led by researchers at The Wistar Institute has shown that an enzyme known as Ubp10 plays a vital role in protecting the telomeric regions of the genome from potential destabilizing molecular events. The enzyme helps to keep the genome structurally closed, unavailable for transcription and possibly protected from dangerous genetic recombinations with other regions of the genome. A report on the research, which was conducted in yeast, appears in the February 18 issue of Molecular Cell.

"There are regions of the genome that have to be inaccessible," says Shelley L. Berger, Ph.D., the Hilary Koprowski Professor in the gene expression and regulation program at Wistar and senior author on the study. "Otherwise, they can recombine with themselves or with other DNA segments. In the telomeres, such events may accelerate aging or trigger cancer in humans."

"We have identified a molecular mechanism to explain how this enzyme helps keep telomeric DNA silenced and potentially protects the genome from destabilizing activity," says N.C. Tolga Emre, a graduate student in Berger's laboratory and lead author on the study.

The Ubp10 enzyme acts o n histones, molecules that have attracted increasing attention from scientists as they move beyond sequencing the human genome to trying to better understand how DNA is managed and its activity regulated. Histones are small proteins around which DNA is coiled to create structures called nucleosomes. Compact strings of nucleosomes, then, form into chromatin, the substructure of chromosomes. In many cases, when the DNA is tightly wrapped around the histones, the genes cannot be accessed and their expression is repressed. When the coils of DNA around the histones are loosened or the histone molecules are altered, the genes become available for expression.

It is the complex activity governing this process to which Ubp10 contributes. Enzymatic modifications to histones control DNA activation or silencing through the addition or removal of acetyl, methyl, and ubiquitin molecules in prescribed sequences and patterns. One job of Ubp10, as identified in this study, is to remove ubiquitin from certain histones where ubiquitin is associated with gene activation and to maintain low levels of the ubiquitin molecule at those sites.

Interestingly, Ubp10 appears to work similarly and in concert with another enzyme called Sir2, which removes acetyl molecules from histones. Sir2 has also been associated with promoting genomic stability, and some studies have linked it intriguingly to the aging process. Some studies, for example, have suggested that low-calorie diets that extend life also boost Sir2 activity dramatically.


'"/>

Source:The Wistar Institute


Related biology news :

1. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
2. Novel Enzyme Shows Potential As An Anti-HIV Target
3. Enzyme allows B cells to resist death, leading to leukemia
4. Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
5. Enzymes newly discovered role may make it target for arthritis treatment
6. Promiscuous Catalytic Activity Possessed by Novel Enzyme Structure
7. Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Enzyme affects hypertension by controlling salt levels in body
10. Enzyme inhibitors block replication of SARS virus
11. Enzyme crystal structure reveals unexpected genome repair functions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: